Table 2.
Adverse Events in Pazopanib Recipients by Age Subgroups (Safety Population)
| Events, n (%) | Age < 65 Years (n = 180) |
Age ≥ 65 Years (n = 60) |
|---|---|---|
| Any on-therapy AE | 178 (99) | 59 (98) |
| AEs related to study treatment | 168 (93) | 51 (85) |
| AEs leading to permanent discontinuation or early withdrawal | 30 (17) | 18 (30) |
| AEs leading to dose reduction | 60 (33) | 17 (28) |
| AEs leading to dose interruption/delay | 89 (49) | 31 (52) |
| Any SAE | 75 (42) | 24 (40) |
| SAEs related to study treatment | 40 (22) | 17 (28) |
| Fatal SAEs | 7 (4) | 1 (2) |
| Fatal SAEs related to study treatment | 1 (< 1) | 0 (0) |
AE adverse event, SAE serious adverse event.